Question-and-Answer Session
Operator
(Operator's Instructions) And our first question will come from Derik De Bruin with UBS.
Derik De Bruin - UBS
Hi, good afternoon. Can you give us just a little bit more color on the Kaiser agreement, I guess? You said that UCSF is buying systems outright. Who validated the platforms, how much work went into it, and how profitable is that agreement going to be?
Kevin M. King
This is Kevin, I'll take that. UCSF did a study of their own using the Axiom platform prior to the agreements being penned if you will, so they ran samples on the Axiom platform. If your question was about who else validated a platform, there were about five other customer sites that validated the platform. The results of those trials, if you will, are on the Axiom.Affymetrix website. There's a poster that's being presented at the ASHG meeting if you'd like to refer to that, and it lists the five customer groups and the results, the size of their samples that were run, and all of the other metrics.
Related to — they are buying gene titan systems. The profitability of the deal, it's a good deal for us. It's a very large deal. And it's a good deal. We're not disclosing the profitability of it, but profitability is pretty decent for us.
Derik De Bruin - UBS
Well, I mean I guess if they're running 100,000 samples, I'm just trying to get a — I guess what does it cost on a per sample basis on the new platform for that type of analysis.
Kevin M. King
So, price varies with volume and the list price for an Axiom per sample I think is in the order of about $250 is the list price on a per sample and it varies there based upon the volume, and I may be off by a couple of dollars on the $250, but I think it's pretty close to that.
Derik De Bruin - UBS
Okay. And then one final question and then I'll get back in the queue. Could you talk a little bit more about the overall US market? You said your DNA business was down about 14% as a temporarily delay, could you just talk about what you're seeing in that market and how you think that's going to evolve? And I guess, could you estimate what do you think your share is of the overall US market?
- To read the full transcript on Seeking Alpha, click here »
